HGH Fragment: A Literature Course in Six Modules

How this course is organised

This is a reading guide, not a protocol. Each of the six modules below summarises what specific published papers on human growth hormone (hGH) fragments actually examined, in the models they used, and each module closes with a short statement of what that evidence cannot support. Only a small, verified set of papers is cited, and every statement about a measured effect carries its citation in the same sentence. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition, medication or laboratory result.

Module 1: What the HGH fragment is and how it has been studied

Human growth hormone is a single protein chain of 191 amino acids. The phrase "HGH fragment" does not name one molecule; it names any shorter stretch of that chain, either produced by cutting the intact hormone or made synthetically from scratch. Fragments are conventionally identified by the residue numbers they span, which is why the literature contains entries such as hGH 4-15, hGH 6-13 and hGH 176-191, alongside larger proteolytic species described by molecular weight, such as a 14-kilodalton fragment.

Forms that appear in the verified literature

• N-terminal region fragments. Short sequences from the beginning of the chain, including hGH 4-15, which researchers tested on isolated rat adipocytes (PMID 3569692), and hGH 6-13, described as a hypoglycaemic fragment and examined for pancreatic effects (PMID 3046817).
• C-terminal region fragments. The segment around residues 176-191 is the region most commonly meant in general conversation about "the HGH fragment". A peptide-chemistry study characterised the C-terminal fragment I179-C182-[SS]-C189-P191 and a related trisulfide form by nuclear magnetic resonance (PMID 9151258), and a laboratory study used hGH fragment 176-191 together with doxorubicin-loaded chitosan nanoparticles in MCF-7 breast cancer cells (PMID 35783198).
• Larger fragments. A 14-kilodalton fragment of human growth hormone was characterised as an inhibitor of angiogenesis and tumour metastasis (PMID 37240223), which places it in a different size class from the short synthetic peptides above.

Class and origin

Chemically, these are peptides — short amino-acid sequences — derived from a protein hormone sequence. That origin matters for interpretation: a fragment is not the hormone. It lacks most of the parent chain and cannot be assumed to reproduce, or to block, the full hormone's receptor activity unless a study tested that directly. The C-terminal region also contains cysteine residues capable of forming a disulfide bridge, and the chemistry work examined both a disulfide and a trisulfide version of the same C-terminal sequence (PMID 9151258), meaning "the same peptide" can exist in more than one covalent form.

Limits of the evidence in Module 1

The verified papers describe different fragments studied by different groups for different purposes across several decades. Nothing in this set establishes a single standardised product, a single accepted name, or equivalence between one fragment and another. Findings about hGH 4-15 cannot be transferred to hGH 176-191, and vice versa.

Module 2: Mechanism as described in the literature

There is no unified mechanism for "HGH fragments" as a category. Each fragment in the verified set was studied for a different described action.

Insulin-like metabolic signalling

In isolated rat adipocytes, researchers reported that an N-terminal human growth hormone fragment, hGH 4-15, stimulated 2-deoxyglucose uptake (PMID 3569692). 2-deoxyglucose uptake is a standard laboratory readout for glucose transport into a cell, so the described mechanism is a metabolic, insulin-like action at the fat cell rather than a growth-hormone-receptor effect on growth.

Pancreatic involvement in glucose lowering

A separate study examined the pancreatic effect of hGH 6-13, a fragment the authors described as hypoglycaemic (PMID 3046817). That framing locates part of the proposed mechanism in pancreatic tissue rather than exclusively in peripheral tissues.

Anti-angiogenic and anti-metastatic activity

The 14-kilodalton fragment was characterised as a potent inhibitor of angiogenesis and tumour metastasis (PMID 37240223). Angiogenesis inhibition describes interference with new blood-vessel formation, a mechanism class studied in oncology and in eye disease, and entirely separate from the metabolic work above.

Interaction with a cytotoxic drug carrier

In cell culture, hGH fragment 176-191 was reported to enhance the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells (PMID 35783198). The mechanism described there is a combination or delivery effect measured in cells, not an independent action of the peptide on body composition.

Structure as a mechanism question

The nuclear magnetic resonance study of the C-terminal fragment and its trisulfide counterpart addressed conformation — the three-dimensional shape the peptide adopts in solution (PMID 9151258). Structural characterisation of this kind is a prerequisite for mechanism work, because a peptide's shape and its sulfur bonding pattern influence whether it can engage a target at all.

Limits of the evidence in Module 2

None of these papers, as cited here, demonstrates a receptor-level mechanism for fat loss in humans. Mechanisms frequently repeated in popular discussion of "HGH fragment" — for example a specific adrenergic receptor pathway driving lipolysis — are not established by any of the five verified studies, and are therefore outside the scope of this course.

Module 3: Reported outcomes, study by study

Reading the table honestly

Two of these papers are cell-free or cell-culture chemistry, two are older laboratory metabolic studies in animal tissue, and one is a tumour-biology characterisation. A result obtained in isolated rat fat cells, such as the stimulation of 2-deoxyglucose uptake by hGH 4-15 (PMID 3569692), describes what happened in that preparation. It is not a statement about human fat mass, waist circumference, insulin sensitivity or body weight, none of which were endpoints in the verified set. Likewise, the enhancement of doxorubicin nanoparticle toxicity in MCF-7 cells (PMID 35783198) is a cancer-pharmacology observation in a dish, not evidence of any general benefit.

Limits of the evidence in Module 3

No randomised controlled trial, no human dosing schedule and no long-term outcome data appear in these papers. Because the verified set contains no human efficacy study, this course makes no benefit claim of any kind for any HGH fragment.

Module 4: HGH Fragment Side Effects: What Studies Report

A truthful answer here begins with the design of the available work. Adverse events are recorded when living participants or animals are dosed and monitored. The verified studies in this course were not safety trials, and none of them reports a human adverse-event table.

• The MCF-7 experiment measured cytotoxicity — cell killing — as its intended outcome when hGH fragment 176-191 was combined with doxorubicin-loaded chitosan nanoparticles (PMID 35783198). In an oncology context that cell death is the goal of the experiment, so it cannot be read either as a safety signal or as a safety clearance for healthy tissue.
• The 14-kilodalton fragment work described inhibition of angiogenesis and tumour metastasis (PMID 37240223). Anti-angiogenic activity is a pharmacological property with recognised biological consequences for tissue that depends on new vessel growth, but this paper as cited does not report a toxicity profile or adverse events in humans.
• The glucose-related studies raise a physiological rather than a reported-adverse-event point: one fragment was described as hypoglycaemic and studied for pancreatic effects (PMID 3046817), and another was reported to stimulate glucose uptake in adipocytes (PMID 3569692). Researchers treated glucose movement as the measured outcome; no clinical hypoglycaemia events in people are described in these papers.
• The structural study of the disulfide and trisulfide C-terminal peptides reports chemistry, not biological safety (PMID 9151258), although the existence of more than one covalent form of a peptide is the kind of purity and identity issue that safety assessment normally has to resolve.

Limits of the evidence in Module 4

Absence of reported adverse events in preclinical chemistry and cell studies is not evidence of safety. Nothing above characterises injection-site reactions, immunogenicity, endocrine effects, interactions with other drugs, or effects in pregnancy, children or people with diabetes, because no verified study examined those questions.

Module 5: Pharmacokinetics, where data exist

For HGH fragments in the verified literature, pharmacokinetic data are essentially absent. None of the five papers cited in this course reports absorption, bioavailability, plasma half-life, volume of distribution, metabolism or renal clearance in humans or animals.

What does exist is upstream chemistry. The nuclear magnetic resonance study characterised the C-terminal human growth hormone fragment I179-C182-[SS]-C189-P191 alongside a related trisulfide peptide (PMID 9151258), and that distinction is relevant to peptide stability and identity: the sulfur bridge configuration determines whether two preparations sharing a sequence are actually the same molecule. General peptide pharmacology also predicts that short unmodified sequences are subject to rapid enzymatic breakdown and poor oral absorption, but that general expectation is not a measurement from any of these papers, and no verified study in this set quantified it for an hGH fragment.

Formulation work is a separate strand. The chitosan nanoparticle study loaded doxorubicin into a carrier and used hGH fragment 176-191 in the same in-vitro system (PMID 35783198), which speaks to delivery-system design in cell culture rather than to how the peptide behaves in a body.

Limits of the evidence in Module 5

With no half-life, no exposure curve and no dose-ranging data in the verified set, any statement about frequency, timing or route for an HGH fragment would be unsupported by the literature summarised here. This course therefore contains no dosing information.

Module 6: Regulatory status, stated factually

Recombinant human growth hormone itself (somatropin) is marketed in the United States and elsewhere as an approved prescription biologic for specified indications. That approval applies to the full-length hormone product, not to peptide fragments of it.

• No approved fragment drug. There is no FDA-approved finished drug product whose active ingredient is hGH fragment 176-191, hGH 4-15, hGH 6-13 or a 14-kilodalton growth hormone fragment. The peptides described in the studies above were used as research materials.
• Research-use-only status. Material supplied for laboratory work is commonly labelled "research use only" or "not for human consumption". That label is a statement that the substance has not been evaluated or authorised as a medicine, and it is not an alternative pathway to human use.
• Compounding. Under US law, a bulk drug substance is eligible for pharmacy compounding only through defined routes — for example being a component of an FDA-approved drug, having an applicable USP monograph, or appearing on FDA's list of bulk drug substances that may be used in compounding. Growth hormone fragment peptides do not hold approved-drug status, and FDA has publicly grouped a number of peptide substances as raising immunogenicity and other safety concerns for compounding.
• Sport. Anti-doping regulations address growth hormone and growth hormone fragments within their prohibited peptide-hormone classes, so athletes subject to testing operate under rules independent of drug-approval status.

Limits of the evidence in Module 6

Regulatory classification is about legal and administrative status, not about biological effect; a substance can be unapproved and still have measurable laboratory activity, as the cited preclinical work illustrates. Rules also change and differ by country and by state. This section is general information, not legal advice.

What the studies did not test

Closing a literature course means naming the gaps as clearly as the findings.

1. Human fat loss. No verified study measured body weight, fat mass, waist circumference or body composition in people. The adipocyte glucose-uptake result (PMID 3569692) is a cell-level transport measurement, not a weight outcome.
2. Dosing. No schedule, quantity, duration or route for human use appears in any cited paper, so none is reproduced here.
3. Safety over time. No study followed participants for adverse events, immunogenicity or endocrine disruption; the anti-angiogenic characterisation (PMID 37240223) and the cancer-cell cytotoxicity work (PMID 35783198) had different aims entirely.
4. Comparisons. No verified study compared a fragment against growth hormone, against placebo, or against an approved medicine in a clinical setting.
5. Special populations and interactions. Pregnancy, childhood, diabetes, cancer treatment and concomitant medication were not studied as safety questions, even where glucose handling was the endpoint (PMID 3046817).
6. Product identity. The demonstration that a C-terminal sequence exists as both disulfide and trisulfide forms (PMID 9151258) underlines that sequence alone does not define a peptide preparation.

Readers comparing this summary with marketing language elsewhere will notice the distance between the two. The published record cited here is narrow, mostly preclinical, and silent on the questions people most often ask. Again, this page is educational only and is not medical advice; a licensed physician is the appropriate source for individual guidance.

References

• The 14-Kilodalton Human Growth Hormone Fragment a Potent Inhibitor of Angiogenesis and Tumor Metastasis (International Journal of Molecular Sciences, 2023)
• Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells (Drug Design, Development and Therapy, 2022)
• Pancreatic effect of a hypoglycaemic fragment of human growth hormone (hGH 6-13) (Diabetes Research, 1988)
• Nuclear magnetic resonance studies of the C-terminal human growth hormone fragment I179-C182-[SS]-C189-P191 and the related trisulfide peptide I179-C182-[SSS]-C189-P191 (The Journal of Peptide Research, 1997)
• Stimulation of 2-deoxyglucose uptake in rat adipocytes by a human growth hormone fragment (hGH 4-15) (Diabetologia, 1986)